Indinavir sulfate

For research use only. Not for therapeutic Use.

  • CAT Number: I002002
  • CAS Number: 157810-81-6
  • Molecular Formula: C36H47N5O4 • H2SO4
  • Molecular Weight: 711.90
  • Purity: ≥95%
Inquiry Now

Indinavir Sulfate(Cat No.:I002002)is a high-purity HIV-1 protease inhibitor widely used in antiviral and pharmaceutical research. It functions by targeting the HIV-1 protease enzyme, preventing the cleavage of viral polyproteins, and thereby halting the maturation of infectious virions. The sulfate form enhances its solubility and stability, making it suitable for various experimental applications. Indinavir Sulfate is instrumental in studying HIV replication mechanisms, drug resistance, and combination antiretroviral therapies. Its efficacy and specificity make it a valuable tool for advancing HIV treatment research and developing innovative therapeutic strategies.


Catalog Number I002002
CAS Number 157810-81-6
Synonyms

Crixivan;L-735,524;MK-639

Molecular Formula C36H47N5O4 • H2SO4
Purity ≥95%
Target Metabolic Enzyme/Protease
Solubility DMSO:~20 mg/ml; DMF:~14 mg/ml; PBS (pH 7.2):~10 mg/ml ;
Storage -20°C
IUPAC Name (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;sulfuric acid
InChI InChI=1S/C36H47N5O4.H2O4S/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43;1-5(2,3)4/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45);(H2,1,2,3,4)/t28-,29+,31+,32-,33+;/m1./s1
InChIKey NUBQKPWHXMGDLP-BDEHJDMKSA-N
SMILES CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5.OS(=O)(=O)O
Reference

<p style=/line-height:25px/>
<br>[1]. Stein, D.S., et al., A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS, 1996. 10(5): p. 485-92.

<br>[2]. Liu, F., et al., Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J Mol Biol, 2005. 354(4): p. 789-800.

</p>

Request a Quote